Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TORISEL
- Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
- Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
- Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
- Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
- Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
- POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer
- Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
- A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
- STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
- Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
- Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
- A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
- Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
- Study of Axitinib and Temsirolimus in Solid Tumors
- BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
- Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- Temsirolimus In Phase 0
- Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
- Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
- Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
- Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
- Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
- Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
- Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
- Hepatocellular Carcinoma (HCC)_Torisel_
- Temsirolimus-RCC-imaging
- Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
- Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
- Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
- Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
- Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
- Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
- Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
- Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
- Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
- Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
- Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
- Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
- Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
- A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
- Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
- Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
- A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
- Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
- Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
- Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
- Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
- Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
- Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
- Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
- Temsirolimus and Radiation for Non-Small Cell Lung Cancer
- Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
- Study of Temsirolimus, Topotecan, and Bortezomib
- Doxil, Bevacizumab and Temsirolimus Trial
- Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
- Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
- Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
- Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
- Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
- Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
- Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
- Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
- Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
- A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
- Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
- Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
- Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
- Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
- Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
- Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
- Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
- Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
- Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
- Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
- CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
- CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
- CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
- Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
- CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
- CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
- CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
Clinical trials list
click for details